hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
Add bookmark
This video presentation demonstrates how hESC derived cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas describes how hESC derived Cytiva Cardiomyocytes: • are a valid model of cardiomyocytes from the human heart • are compatible with assays routinely used for testing cardiotoxicity • together with high-content assays and analysis, can indicate the mechanism of toxicity of drug compounds By entering in your information&n...
Tags:
cardiotoxicity
Human embryonic stem cell-derived
hESC
clinically predictive cardiotoxicity assays
cardiac drug liabilities
hESC derived cardiomyocytes
GE
drug safety testing
toxicity
high-content assays
Cytiva Cardiomyocytes
Nick Thomas
cell model
